By Pyroxlabs
Research Use Only: This article is intended strictly for laboratory research purposes. Nothing in it should be interpreted as medical, dosing, or usage advice.
Selank, Semax, and DSIP are commonly grouped together in commercial peptide literature as “nootropic” or “cognitive” research compounds, often with an implied shared origin. The reality is more nuanced — two of the three share a genuine research lineage, while the third comes from an entirely different scientific tradition with a much more contested evidence base. Here’s an honest breakdown.
Selank and Semax: a real shared lineage
Selank and Semax were both developed at the Institute of Molecular Genetics, Russian Academy of Sciences, share the same stabilising Pro-Gly-Pro (“glyproline”) structural motif, and have overlapping research investigators. That’s where the similarity ends structurally: Selank is a tuftsin analogue studied primarily for anxiolytic and immunomodulatory effects, while Semax is an ACTH(4–10) analogue studied primarily for neurotrophin (BDNF/NGF) signalling and, in Russian clinical research, stroke recovery. Semax also carries a pharmaceutical registration history in Russia that Selank does not share to the same degree. See our full Selank Research Guide and Semax Research Guide.
DSIP: a different tradition, and a genuinely contested one
DSIP has a different scientific history altogether — discovered in Switzerland in the 1970s, later studied by Soviet groups, but not part of the same Institute of Molecular Genetics research programme as Selank and Semax. More importantly, DSIP’s very existence as a discrete, well-characterised endogenous peptide is questioned in the modern literature: a widely cited 2006 review in the Journal of Neurochemistry describes it as “a still unresolved riddle,” noting that the original sleep-inducing effect has not been reliably replicated and that observed effects may reflect carrier-bound, DSIP-like immunoreactive material rather than a single defined peptide. Grouping DSIP with Selank and Semax as “the same family” — as some commercial sources do — isn’t scientifically accurate. See our full DSIP Research Guide.
A shared pattern across all three
Despite their differences, Selank, Semax, and DSIP share some common threads worth understanding as a category: overwhelmingly non-Western research provenance (Soviet/Russian, or Swiss-then-Soviet-continued for DSIP), small human study sample sizes, weak or unreported blinding/controls by modern standards in much of the older literature, and little to no independent Western replication. None of this means the compounds are without research interest — it means researchers should approach the published literature for all three with appropriate scientific caution, rather than treating commercial “nootropic stack” framing as equivalent to an established evidence base.
FAQ
Which of the three has the strongest evidence?
Semax, on balance — it has the most substantial human clinical research (stroke recovery studies) and an actual regulatory registration history, though still limited by dated, non-Western trial design.
Should Selank, Semax, and DSIP be studied together as a “stack”?
Published literature does not support treating these as an established combination — each has been studied independently, and DSIP in particular has a fundamentally different (and more contested) research basis than the other two.
Can Pyrox Labs advise on research protocol design for these compounds?
No. We supply tested, research-grade material with full batch documentation, but we don’t provide protocol design or usage advice.
Research Use Disclaimer: All products discussed are intended solely for in-vitro laboratory research and are not for human consumption, veterinary use, or any form of personal use. By purchasing, you confirm you are a qualified researcher or institution and agree to our full Research Use Disclaimer and Terms & Conditions.
Related guides: Selank Research Guide · Semax Research Guide · DSIP Research Guide
